The European Commission’s proposed methodologies for performing EU-wide joint clinical assessments (JCAs) for medicinal products, a key part of the wider health technology assessment Regulation, are open to public scrutiny until 2 April.
The 18-page draft JCA implementing act document sets out a proposed framework for rolling out JCAs under the new HTA Regulation, including the roles of different entities involved, such as the JCA subgroup, the HTA Coordination Group and the commission itself
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?